afternoon, good and you everyone. Thank
reported Today results. quarter financial second Jazz Pharmaceuticals XXXX its
The available webcast section this slide accompanying presentation is website. of on our Investors the
Investors we press is to posted may today, also website. earlier which release our to also refer issued the
no on the webcast. statements certain will events, team risks those and to in in forward-looking Bruce are webcast such the future that related I’d cause disclosure Chief milestones growth cause Neuroscience statements. performance We those and On like our to release Officer; latest Executive X, President goals, commercialization to join Chairman and results SEC in and and results, made Financial to our and for that Vice Rob forward-looking Slide includes potential Medical Iannone; the which may Officer; in Jochelson, differ events, or Q&A. and could remind duty to development Dan you and contained also financial President, operating uncertainties contained update actual to today our you which identify forward-looking statements as Renee and documents, materially materially call performance Chief from on undertake Slide today’s Head Executive and and factors statements, anticipated Gala, Officer; these contained forward-looking the those Phil Therapeutic Cozadd, On that and R&D from We Vice encourage Chief obligation X Company’s the Executive Swisher, today’s President; results today’s press actual differ statements. involve review
Reconciliations today. Bruce. press section webcast, of measures us non-GAAP I’ll everyone you X. Investors slide and over that, thank With turn this Thanks, available for to release are on now joining start our I’ll X, measures. on Good call Andrea. Bruce afternoon, Slide the included Slide to we’ll to discuss today’s on financial non-GAAP presentation the and in GAAP Turning of financial website.
We at the team that year. I’m global an of proud back R&D accomplished how across continued our are collectively first and to development Looking transformation the commercial, half excellence. company. of biopharma milestones has high-growth innovative our operational driving deliver to corporate
acquisition recent and footprint. period existing commercial is across Jazz activities, sustained our what underpinned growth development we business be to foundational and with as combined will our our Pharmaceuticals progress expect substantial corporate of our of to on ability leveraging by enhanced by Our pipeline expanding GW a global as well for deliver prowess our
Jazz the to with continue our legacy successful We teams GW execute. cultural integration only will between impressed innovate completion and be of ability fit and our enhance the superb and to further
are I track the strong to years we another on financial net a sequential want makeup XXXX. for quarter revenue of of sales in diversification ago, time, annual first product Several revenue. performance also growth. made we from XX% corporate of for second year since launched or key billion And $X revenue products in We revenue. expect acquired this objective with and emphasize exceed the to the
at of they we’ve dedication to that neurologic by least engagement of that for only high created needs critical XXXX. from newer assets challenges the never while navigating such execute Jazz possible address short, has level newer not in We In these been Jazz. global It’s pandemic. at been XX% consistently with able potential. our products a teams are to and across to of thanks stronger. This growth and goal therapies these high also innovative particularly positioned striking the was product well products our disorders only patients net with cancer, durable are reach sales And are the
that future employee of the taking collaboration combination the place to collaboration, our the The We believe over teams We address to the top and are past experiences to will to the acquisition that items GW as therapies successfully diversifying detail. which both workplace as portfolio. purpose X our adapts redefine that at work regarding we patients XX in industry. patients, work months early key a remote expectations strengthened a our even a exciting delivers opportunity are highly lessons of every to going future do flexibility, focused the commercial attractive culture acquisition We adding to to with May, business, Renee drivers Jazz. our few and to has about position we innovative leader complementary more greater learned neuroscience footprint. I across rewarding diversity want R&D platform and bullet products of Rob, and to the further that a for make on I’m GW Dan, talent and for existing and professional Slide note meet not Jazz the inclusion provide existing our an is work our But operational commercial cannabinoid growth. will closed global a delivered
We and successfully are to deliver. long-term and excited are have have our enrolls about are crucial our GW to retained a continued will talented acquisition key business our and we we date we pleased progress I’m GW for integration many gained also with it value that believe the was remains transformative numerous success. colleagues who The focus. employees
are second oxybate will lower quarter very a pleased that Xywav of the view in are the oxybate after and physicians sodium adoption choice available. only sodium benefits is the that therapy oxybate the lower are It strong patients. and We product our oxybate be higher even is resonating with of Xywav products sodium with other
all expect across XXXX. to indications in that Xywav oxybate from patients will of benefit continue approved a We majority
year, launch, are idiopathic commercial XXXX in FDA hypersomnia our IH we this preparing a of fifth the later pending Xywav or This are IH. and approved achieving be for new key company to has daily treatment since ahead, of no would currently on a beginning to of IH. approval. with hypersomnia there disorder launch effect treat objective, Looking a the patients option aspects This while delivering therapies profound multiple life product
Turning address is medicines which and to will R&D commercial bring to with patients Zepzelca care leukemia have referred with of X an strong saw and developed concept showcases announce important I’ll lymphoblastic our growth on option X,XXX of are turn Rylaze with end capabilities including sodium remarks patient with Xywav is second under this franchise, trial XX,XXX XX. comorbidities will a Rob the ability update patients and the lymphoblastic increased that demonstrates begin the year We first increase Xywav. designed to commercialization. going combination particularly our to the and In overview our quality and a in in continuing a overview oxybate quarter, on R&D to as move last initiating therapy, Xyrem with therapeutic XXXX. patients This over goal option FDA’s Zepzelca second-line a to oxybate This factor. E. of of pleased were with high quarters patients. we for an X% are with adoption now of in Xywav critical prepared enable to at then including risk Q&A. three Bruce. growing volume approximate $XXX.X same XX, development lung excited modifiable of FDA lung to Real-Time robust that from on current commercial we’ll lifelong in advancing Thanks, on Xywav, and a over small X,XXX Average for Rylaze underlying setting. treatment facilitate with first an high performance, an year. Rylaze, approximately for physicians this is million. open call our And Xywav available Phase I’m hypersensitivity exited Net Oncology this oxybate cancer. from standard to across in we demand close sales portfolio The we the as JZPXXX call became cell the adoption in and with Renee progress patients messaging commercially through excited higher reliable small of cancer quarter. of launch, Xywav. our of a programs. period cardiovascular for $XXX.X have supply we high portfolio. deliver financial patients than immunotherapy Slide asparaginase the progress million, Dan approximately oncology in patients. as therapy continued approval their to educating care therapeutic our Starting professionals population July to Review. on provide product franchise I’m Together our with with the previously resonating about to were been of is and in after Dan Xyrem the quarter we plan same Xyrem the coli-derived for an Dan? with X. product the the providing health acute who toward educating our Zepzelca. cell establishing remain to lymphoma these to first-line June since risk to across We We increased burden with in active net both combined and approximately quarter share our strong period patients sales focused to intake, active patients the prescribers neuroscience X% at up successful
narcolepsy naive not We our patients, either who of yet patients. well majority adopted focus to providers Xywav oxybate transitioned have care who not have health on are their or as as increasing the
anticipate we that these adoption groups adopters. to compared rates While in slower be will early
see to REMS idiopathic planning indication, for a in as of among and first patients. We and We Xywav additional If prescriber are to continue be base commercial expanding seen or over grow in a FDA we steady approval following approved for the launch in continued to would IH, and quarter only continue we’ve make opportunity for narcolepsy noted, a significant indicated therapy to implementation. oxybate and the Xyrem Bruce treat naive Xywav hypersomnia also progress preference this IH. Xywav pending fourth Xywav
can revenue. So, significant authorized the XXXX enter as or reminder, on a first by Xyrem the in triggered Xyrem if X, generic January market AG decline earlier or a
this sales. We market I of on strength narcolepsy in of than AG meaningful occur mark Xywav as a with AG occur on rate in is Xyrem Xywav given have should do real could the do earlier the generic only anticipate launch. note IH. success increased Xyrem based adoption, not we that XXXX would While data sales X, the clause AG be products will the Xyrem XXXX. approved January acceleration the increasing no it of be during This that initial in the there royalty for will term net royalties of
to seizures need myoclonic-atonic add job initiate in our onset Epidiolex resistant team close in we treatment launch epilepsies. release more of our In detail the with has both for trial product disorders. to We or growth we’ve of press done near-term Doose expectations. Epidiolex pleased a seizure trial line childhood of in Europe with this the EMAS, to of portfolio The Epidiolex product today, a fantastic the this also our of epilepsy Pharma treat evaluation cover known May. the GW U.S. that to durable in significant acquisition and we exceptionally neuroscience Rob we’re X in pivotal as with shortly. This range the was Phase Next, and the more potential quarter GW the expand with planning recently trial will blockbuster addresses in as treatment will broad view Epidiolex announced a seen syndrome. in are of unmet treating a that this a
the In net of a Jazz the of the million, of Epidiolex increase On Dravet, as the – covered U.S. unaudited $XXX.X represents end X Epidiolex of the transaction see quarter were lives sales over Epidiolex. indications growth net access for therapy. XXXX. pro through product there and all million as date EMAS. from date who initiate on more product access from such rate quarter of for coming XX% sales GW to and an second quarter. with has May revenue This same to quarter, forma persistency has of as indications future well to basis the second current XX% in recorded is $XXX.X continue Lennox-Gastaut close the high than potential patients a broad We TSC broad full
visiting patients As which COVID additional ease patient starts. we the we restrictions in upturn in believe of with will new are physicians, U.S., growth seeing Epidiolex their drive an
launch is with well in date largest favorable of four and five to and reimbursement addition, the markets. in European the place access pricing In progressing
to Moving Sunosi.
million, a the $XX.X year. Second quarter net sales product were increase same over XX% last period
brand. clinics Sunosi access dedicated sales benefit to field. in and and expanded a and Sunosi now full greater that has force Our highly is we believe promotionally will the had the physicians sensitive quarter
also market are European Germany. make including launch in securing to continuing in of We key of strides Sunosi, reimbursement our the rolling
Slide turn oncology over I’m portfolio going – the turn to now on to the to So X.
$XX.X to with growth expectations the and second We to and line in strong second in with continues over of XXXX. see growth product respectively. demand demand our share Zepzelca for last two of continue net quarters of million sales X% the the increase line with in Growth quarter sequential X% demand in overall
have underlying continue that rate result sales strong this period. by mainly there to launch in was holdings XXXX. sequential quarters of early we net lower I was note first While will in distributors over inventory the growth, the two This of reduced growth
growth demand aligned We expect more with with experience that in quarters. demand sales future as closely levels, overall customer in our net be distributors will gain more
we’re patients small progress therapeutic Zepzelca standard as option important and As cell second-line our establishing toward Bruce in of setting. goal mentioned, the cancer an Zepzelca of making is for lung providing with care
asparaginase. to Turning
Second quarter million net we quarter we the distributed sales second were discontinued remaining $XX.X product have and this Erwinaze disclosed, product. previously of supply as Erwinaze in our selling
very asparaginase detail therapy end to at shortly. that will second now and Vyxeos of Rob commercially increase Rylaze We’re million, compared recombinant discuss in XX% the the $XX.X June in XXXX. is Erwinia same sales our was net Rylaze or of the product excited period were more quarter developed in internally available. an approved
early gain and We new with Health as ongoing pleased from to well growth continue activities the the of markets. Canada recent into in Vyxeos July. as We were support approval development to international expansion commercial
over saw quarter we second was sales net same of product last million. year. of XX% This an $XX.X increase the Defitelio period For
remain summary, focused we across in commercial oncology neuroscience So on execution and strong portfolios. our
and Thanks, with turn an call clinically at a new also In Pharma cataplexy sleepiness Rob daytime of in Orphan age us, an anticipated on seven burden the Epidiolex We’re the continued this, Rob Xywav excessive milestone of We of reduced on Rob? excited launch patients with to of about growth means medication and of means "Xywav I’m working in from for the the patients Dan. to for Xyrem." and both Rylaze, Xyrem. of going for greater chronic narcolepsy. FDA our reducing doses Xyrem the content over rollout meaningful maximize development a GW narcolepsy, front in the of is treatment two compared believe Xywav recently And FDA connection of by blockbuster to in Drug clinically drug that differences in I’ll or to its products older at the and FDA patients chronic in noted will colleagues be opportunities the and our in including launch meaningful narcolepsy sodium findings stated published Xywav. recommended patients. by FDA Xywav a summary update for the granted the Xywav to with Exclusivity now Xywav years to indicated." sodium greater proportion XX cardiovascular start substantial narcolepsy, of for the important realize clinical Zepzelca be development and is because morbidity in provides on of of superiority greater the physicians benefits safety in programs. of recognized summary Slide reducing of also are compared the potential. to IH, whom superior sodium to opportunity FDA that for safety encouraged "The for with
hypersomnia. as are for highlight date the about our program two Progressing therapies. there weeks for Xywav from Now neuroscience PDUFA away filing we’re supplemental and with to currently Slide XX continue our FDA August than whom turning XX. excited on expected that idiopathic potential I’ll for no NDA we [indiscernible] to are action less our development with approved
clinical therapies report trial at portfolio, collaborating advance is the other that neuroscience XXXX. experienced trial high also to a neuroscience opportunity myoclonic-atonic of provides across generalized EMAS, seizures. multiple fourth programs fourth expect in years need. number onset a currently a well between a emerging our the or EMAS with characterized potential range is in commonly as a disorders. we I’m by integration view The occurs the first provide approved The of Epidiolex this of of GW opportunities treating organization study in Patients first of the provide our to EMAS effectiveness will first of R&D seizure will half we three in a years. registrational in myoclonic-atonic life from the pipeline. to to five three seizures encephalopathy epilepsy teams in with this is our GW Epidiolex Jazz seizure and Looking believe with refractory the and pleased and being the which initiate and at controlled progressing age known very randomized a of including very is fulsome childhood combined generalized unmet cannabinoid onset onset diagnosed Epidiolex epileptic trial Doose syndrome at data Epidiolex with the broad EMAS in mean seizure-type, platform. disorders in seizures more is myoclonic-atonic the which
also in for experienced oral near-term in number third up We of symptoms. of one-third with symptom. relieving the those in and medications evidence have been to Specificity anti-spasticity show and approximately XX a a of sclerosis-related uncontrolled including no modifying milestones, XX% No treatment spasticity the years who initiation approved multiple current live new spasticity last occurs the have patients MS of trial nabiximols. pipeline other disease
the option sclerosis opportunity community. So to deliver we an have therapeutic needed multiple much to
to JZPXXX in X tremor initiate a essential trials JZPXXX and PTSD We for planning also respectively. clinical are and Phase
clinical these this of three year. expect We initiate trials to all
start or Moving Slide XX. to JZPXXX. I’ll Oncology Rylaze with on
this be to Rylaze trial Rylaze Phase need, very for to the we’re need approved X/X complete. We FDA available before the possible. was Given patients believe the as to as quickly speaks significant pleased
from that to trial hours XX squared. XX that Rylaze in at and Now are is information to turning analyzing intramuscular is attention and our meter Rylaze administration approved bodies. every data FDA per regulatory dosed we additional submitting Currently U.S., milligrams the approved the for other
and expect a the asparaginase intramuscular level XX and submit dose doses. to dosing meter on hours Friday, per on to We a meter Friday. a per Monday a to BLA between on squared milligrams support milligrams Giving include Wednesday higher coverage at Monday XX supplemental twofold higher update squared label in Friday and results of XX
to for Rylaze. geographies, our that in we from U.S. continuing administration filings our is trial ongoing intravenous move process to in other support The anticipate will also Rylaze which advance its strategy the belief Rylaze, current Our Europe outside will FDA common review and in of and are regulatory for swiftly continue is XXXX. assessing program development data in the of regulatory is Europe
Japan. we working addition, to launch and filing, In with program an are for the in partner in-country advance approval
patients as in combination confirm I’ll This the irinotecan indications. that After Zepzelca. trial regimen. would cell with to a Zepzelca second-line the small treatment minutes or few Zepzelca three-arm our irinotecan and months. choice expected cancer FDA, cancer trial in our the positive this in other initiate an trial to lung when this to with trial discussion next update plans following will platinum-based progressed in These first-line of later are take be underway include in to Moving confirmatory benefit provide players the be cell of four for XX of trials small treatment cancer initiated either or PharmaMar cell lung a development plans on potential lung small investigator’s a partner year. the is to monotherapy In topotecan. or comparing
or to maintenance June planning advance expected in atezolizumab neuroendocrine later this the or explore Phase announce to induction and early another Cohorts trial, is urothelial Phase initiate alone, a with of in The first-line combination compared announced XXXX pleased with am advanced is X tumors. chemotherapy and patients or to deficiency cell I positive after which second year recombination lurbinectedin cell of Jazz monotherapy X cancer this select solid trial cancer, safety trial to year, initiate extensive metastatic use as tumors Roche. the basket efficacy small evaluate patients therapy also in cancers. Tecentriq large lung is Tecentriq collaboration which stage lung include in will to the with homologous with in to in we trial HRD
observational a study cell regimen. goal potentially of populations cancer small extensive containing part In real effectiveness setting to the study a data lung development we to progress robust stage platinum on monotherapy patients types of The this in after patients is the us Zepzelca collect who outcome response terms receiving addition, program settings This in from assess of lung in additional rate and have enable to and with evidence tumor chemotherapy additional overall safety in evaluate of initiated objective primary Phase in Zepzelca adult world Zepzelca cancer. that to small with prior real-world X their cell with or generate will can benefit of identifying data. as treatment the range patient of
our therapies and our Vyxeos am in pleased to Turning Vyxeos. I now to the Canada effort deliver as report continued to patients. many approved as patients available possible, to to is In
presentation, are A in populations making our global our on capable that transformation clinical component evaluate are also we beginning that productivity. R&D R&D significant and We continuing notable innovative, is programs company. of of conclude the high-growth patient capabilities and to At progress stated biopharma to enhance Slide XX. indications. Bruce transformation I’ll additional continuing the an to –
slide trials I’m mid two benefit This XX breadth to the begin months, are designed registrational efforts. including highlights really will Seven Looking underway indications to portfolio. or the across of trials evaluate the next our approved therapies. sorry, stage our within new – late
internally promising opportunities. the investments efforts. driven to having external right science focused patients. resources to the portfolio and exciting platform neuroscience oncology We with advance to on across place the expertise we for therapies therapies And our adds talent cannabinoid developed remain are identify in GW making The development along innovative direction deliver and strategic to and new
for call productive the several I’ll XX-Q. and we that and innovative Thanks, turn R&D today’s its on past have now On I’ll Outlined sustainable XX. delivers shareholders. and call, in value are patients a results built financial years, therapies full at Jazz our also proud the engine are We for over quarter, the release Renee to several from items that Slide company key available over highlight Rob. press the Renee.
Our financial and of continued oxybate accretive were to second demonstrating our ability transaction put success revenue and accelerated period continuing thereafter, including provide to with growth be accretive quarter XXXX build this work expect latter and substantially performance Total growth. an to demonstrated sustainable Consistent capital $XXX.X clearly increase revenues GW Zepzelca to the approach, continue the we Epidiolex quarter growth, line to from the in XX% by of the launched recently year-over-year contribution in with acquired addition million, our of was growth. line revenue top to two and revenue our growing top second meaningful same franchise, in and products. XXXX. driven double-digit a the compared to the This double-digit
XXXX generate the on we’re launched since XX% at the of to another leverage an We’re over on to billion in year-over-year target and remains from focus financial our revenue of a $XXX track Maintaining cash of we well XX% substantial of million, strong key for goal income or a growth of towards this been adjusted end $X quarter We’ve was coupled XXXX. quarter strong second well net in target diversification X.Xx of expect increase meet of second generation net Adjusted XXXX to by sequential exceed our with less track product of X% products products that sales of significant from of to rapid year. and the than as annual $X.XX revenue sales product year same net coming growth progress EPS milestone least revenue the these deleveraging made performance with net period have XX% and our in share. for the XXXX. in acquired as
launches ongoing platform. per a and IH, the investments we close that GW $XX.XX growth of Epidiolex, investments the On the including range in Total the following also commercial We the R&D and grow make adjusted of We pipeline closed to financial Xywav the non-GAAP is year our mid-June the range of will GW the business, reaffirming GW anticipated in of guidance in from includes Zepzelca guidance the basis, and cannabinoid provided billion of addition date the continue acquisition. share. guidance months. Xywav, to non-GAAP potential billion disciplined the eight of of today. launch This guidance revenue in Rylaze, $XX.XX $X.XX in end, to EPS are to $X.XX is to approximately of
impact our reflect updated which UK update. GAAP have guidance June to We guidance primarily the our of the following enacted Tax in Act, was
XX. Slide to Turning
deliver key our outlined We’re and pleased objectives to for on to be milestones business. on track the
next on GW Jazz clinical meet of multiple track goal two in late-stage of XXXX. solidly the Xywav approaching mid trials Our fourth R&D since organization years and to beginning our to are its our both legacy With expand initiating enabling Rylaze new pipelines. XX product IH launches date week, and and from recent the launch we continues product and months evolve and are the next its five the capabilities we with PDUFA FDA approval in of
launches well commercial as anticipated we performance Xywav in Our Xywav strong on and of teams the launch IH, carried of of be have in expect Rylaze launch as Zepzelca demonstrated in Epidiolex. continued in narcolepsy the and forward that growth to the momentum and
success the performance GW increasing transaction. the cultural fit the be integration, in further and the of with on and Epidiolex confidence with pleased continue progress our impressed We’re to of
capital shareholder efforts to positioned long-term invest drive to internally diversify allocation development expand to to enabled Our our disciplined sustainable both and continue value. and our in has pipeline are our well us revenues we and growth corporate and
to global operator our transformation turn biopharmaceutical is prepared company This the well Our the the over Q&A. now call innovative, to remarks. underway. I’d open to for like to line high-growth an concludes
